User:Mr. Ibrahem/Cryoprecipitate

Cryoprecipitate, also called cryo, is a blood product made from blood plasma. Uses include blood clotting problems, such as obstetrical bleeding or DIC, due to low fibrinogen; and congenital afibrinogenemia. While it has be used for hemophilia A or von Willebrand disease, more specific clotting factor concentrates are preferred. It is given by injection into a vein. Cross-matching (compatibility testing) is not required, though matching the ABO groups is preferred if possible. It is often given to adults as two 5-unit pools.

Side effects may include fever, allergic reactions, acute hemolytic reaction, TRALI, and infections. It should generally not be used in urinary tract bleeding. It is made by thawing fresh frozen plasma at 4 °C then centrifuging and collecting the precipitate. This is then resuspended in a small amount of residual plasma (generally 15 to 30 mL) and is re-frozen for storage. It contains factor VIII, von Willebrand factor (VWF), fibrinogen, fibronectin, and factor XIII.

Cryoprecipitate was developed in 1964 by Judith Pool. It was the first treatment for hemophilia A. It is on the World Health Organization's List of Essential Medicines. It can be stored at -25 °C for up to a year and a half. After thawing and at room temperature it should be used within 4 hours. It costs the NHS about £181 in the United Kingdom for a 5 unit pooled dose of cryoprecipitate. It is less expensive then fibrinogen concentrate.